CompletedPhase 2

Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis

United States13 participantsStarted 2008-07

Plain-language summary

The purpose of this study is to assess the safety, tolerability, and efficacy of AEB071 as a therapy for uveitis. Vision improvement and reduction in the swelling of retina will be measured for the assessment of efficacy.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Serpiginous choroidopathy
✕. Acute multifocal placoid pigment epitheliopathy
✕. White dot retino-choroidopathies (e.g., multiple evanescent white dot syndrome (MEWDS) or multifocal choroiditis)

What they're measuring

Safety and tolerability of AEB071

Timeframe: Baseline/Day 1 to Week 8 (Day 56) (end of study)

Trial details

NCT IDNCT00615693

SponsorNovartis

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-10

View on ClinicalTrials.gov More Uveitis trials